159 related articles for article (PubMed ID: 36304151)
1. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China.
Leng B; Shen C; Gao T; Zhao K; Zhao X; Guo Y; Wu J; Yang J; Fang W; Zhang J; Zhang Y; Sun C; Duan L; Huang J; Qi Y; Yan G
Front Pharmacol; 2022; 13():943674. PubMed ID: 36304151
[No Abstract] [Full Text] [Related]
2. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
3. Risk Factors for Tigecycline-Associated Hypofibrinogenemia.
Liu J; Yan Y; Zhang F
Ther Clin Risk Manag; 2021; 17():325-332. PubMed ID: 33888987
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia.
Lei H; Liu X; Li Z; Wang C
J Chemother; 2023 Jul; 35(4):292-297. PubMed ID: 35904191
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline-associated hypofibrinogenemia in a real-world setting.
Campany-Herrero D; Larrosa-Garcia M; Lalueza-Broto P; Rivera-Sánchez L; Espinosa-Pereiro J; Mestre-Torres J; Pigrau-Serrallach C
Int J Clin Pharm; 2020 Aug; 42(4):1184-1189. PubMed ID: 32504166
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study.
Firat O; Kara E; Malkan ÜY; Demirkan K; Inkaya AÇ
Thromb Res; 2024 Apr; 236():155-160. PubMed ID: 38452447
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study.
Xie W; Ma K; Xu Z; Xie J; Lu X; Wang X
Transl Androl Urol; 2022 Oct; 11(10):1410-1418. PubMed ID: 36386261
[TBL] [Abstract][Full Text] [Related]
8. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia.
Wu X; Zhao P; Dong L; Zhang X
Medicine (Baltimore); 2017 Dec; 96(49):e9124. PubMed ID: 29245350
[TBL] [Abstract][Full Text] [Related]
9. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.
Lin C; Tan M; Wang D; Gu C; Wu Y; Wang S
Pharmacology; 2023; 108(6):540-549. PubMed ID: 37751720
[TBL] [Abstract][Full Text] [Related]
10. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.
Fan Q; Huang W; Weng Y; Xie X; Shi Z
Medicine (Baltimore); 2020 Oct; 99(43):e22638. PubMed ID: 33120753
[TBL] [Abstract][Full Text] [Related]
11. Impact of tigecycline versus imipenem-cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study.
Hakeam HA; Al Duhailib Z; Salahuddin N; Amin T
J Chemother; 2018 Jul; 30(4):224-232. PubMed ID: 29565228
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China.
Chen Y; Zhu D; Zhang Y; Zhao Y; Chen G; Li P; Xu L; Yan P; Hickman MA; Xu X; Tawadrous M; Wible M
Ther Clin Risk Manag; 2018; 14():2327-2339. PubMed ID: 30584308
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for tigecycline-induced hypofibrinogenaemia.
Zhang Q; Wang J; Liu H; Ma W; Zhou S; Zhou J
J Clin Pharm Ther; 2020 Dec; 45(6):1434-1441. PubMed ID: 32860258
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
[TBL] [Abstract][Full Text] [Related]
16. Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study.
Yang X; Jin L; Luo X; Wang M; Zhu H; Zhou Y; Ge W
Int J Infect Dis; 2022 Oct; 123():136-142. PubMed ID: 36028209
[TBL] [Abstract][Full Text] [Related]
17. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E;
BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177
[TBL] [Abstract][Full Text] [Related]
18. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database.
Guo M; Liang J; Li D; Zhao Y; Xu W; Wang L; Cui X
Thromb J; 2022 Mar; 20(1):12. PubMed ID: 35248072
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Bleeding Risk Between Colistin-Tigecycline and Colistin-Carbapenem Treatment Regimens: A Retrospective Cohort Study.
Huang YT; Yu CI; Chen PY; Wang CC; Wu CC
Infect Drug Resist; 2021; 14():4949-4955. PubMed ID: 34858035
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
